Pharmacist Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag conventional-therapy

Blue Note leukaemia DTx gets FDA breakthrough tag

pharmaphorum

JANUARY 11, 2022

Breakthrough designations can speed up the development of new therapies, making them available to patients sooner. It is well-established for conventional drugs and medical devices but has only recently started to be used for DTx. The post Blue Note leukaemia DTx gets FDA breakthrough tag appeared first on.

Chemotherapy

Chemotherapy Hospitals

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

JUNE 29, 2022

This year has already been eventful when it comes to the development of therapies for rare diseases. Additionally, pricing and access for rare disease therapies continue to be scrutinized closely. Most, if not all, of these therapies used the FDA’s Orphan Drug Designation to aid their development plans.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development

Blue Note leukaemia DTx gets FDA breakthrough tag

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Stay Connected